• Carmen García-De-Vicuña, Manuel Díaz-Llopis, David Salom, Rosa Bou, Jesus Díaz-Cascajosa, Miguel Cordero-Coma, Gabriela Ortega, Norberto Ortego-Centeno, Marta Suarez-De-Figueroa, Juan Cruz-Martínez, Alex Fonollosa, Ricardo Blanco, Ángel María García-Aparicio, Jose M Benítez-Del-Castillo, and Jordi Antón.
• Ophthalmology Department, Hospital Sant Joan de Déu, Universidad de Barcelona, Passeig Sant Joan de Déu 2, Esplugues de Llobregat, 08950 Barcelona, Spain.
• Mediators Inflamm. 2013 Jan 1; 2013: 560632.

PurposeTo assess the efficacy and safety of adalimumab in patients with juvenile idiopathic arthritis (JIA) and associated refractory uveitis.DesignMulticenter, prospective case series.MethodsThirty-nine patients (mean [SD] age of 11.5 [7.9] years) with JIA-associated uveitis who were either not responsive to standard immunosuppressive therapy or intolerant to it were enrolled. Patients aged 13-17 years were treated with 40 mg of adalimumab every other week for 6 months and those aged 4-12 years received 24 mg/m(2) body surface.ResultsInflammation of the anterior chamber (2.02 [1.16] versus 0.42 [0.62]) and of the posterior segment (2.38 [2.97] versus 0.35 [0.71] decreased significantly between baseline and the final visit (P < 0.001). The mean (SD) macular thickness at baseline was 304.54 (125.03)  μ and at the end of follow-up was 230.87 (31.12)  μ (P < 0.014). Baseline immunosuppression load was 8.10 (3.99) as compared with 5.08 (3.76) at the final visit (P < 0.001). The mean dose of corticosteroids also decreased from 0.25 (0.43) to 0 (0.02) mg (P < 0.001). No significant side effects requiring discontinuation of therapy were observed.ConclusionAdalimumab seems to be an effective and safe treatment for JIA-associated refractory uveitis and may reduce steroid requirement.

28 keywords...

hide…